

## Press release

EQL PHARMA

Lund, March 27<sup>th</sup>, 2026  
EQL Pharma AB (publ)  
556713-3425

# EQL Pharma CEO sells shares to finance capital gains tax from option redemption

**EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025.**

Axel Schörling has sold 24,066 shares and holds 389,892 shares in EQL Pharma after the sale. The sale corresponded to 5.8% of Schörling's total holdings.

For further information, please contact:  
Axel Schörling

CEO, EQL Pharma AB (publ)  
Phone: +46 (0) 76 317 90 60  
E-mail: [axel.schorling@eqlpharma.com](mailto:axel.schorling@eqlpharma.com)  
Website: [www.eqlpharma.com](http://www.eqlpharma.com)

### EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, ie pharmaceuticals that are medically equivalent to reference pharmaceuticals. The company currently has upwards of 47 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2026 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.